ATE276275T1 - Mhc-komplexe und ihre verwendungen - Google Patents

Mhc-komplexe und ihre verwendungen

Info

Publication number
ATE276275T1
ATE276275T1 AT97905709T AT97905709T ATE276275T1 AT E276275 T1 ATE276275 T1 AT E276275T1 AT 97905709 T AT97905709 T AT 97905709T AT 97905709 T AT97905709 T AT 97905709T AT E276275 T1 ATE276275 T1 AT E276275T1
Authority
AT
Austria
Prior art keywords
mhc
complexes
peptide
image
covalently linked
Prior art date
Application number
AT97905709T
Other languages
English (en)
Inventor
Peter R Rhode
Jin-An Jiao
Martin Burkhardt
Hing C Wong
Original Assignee
Altor Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience Corp filed Critical Altor Bioscience Corp
Application granted granted Critical
Publication of ATE276275T1 publication Critical patent/ATE276275T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
AT97905709T 1996-01-31 1997-01-30 Mhc-komplexe und ihre verwendungen ATE276275T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/596,387 US5869270A (en) 1996-01-31 1996-01-31 Single chain MHC complexes and uses thereof
PCT/US1997/001617 WO1997028191A1 (en) 1996-01-31 1997-01-30 Mhc complexes and uses thereof

Publications (1)

Publication Number Publication Date
ATE276275T1 true ATE276275T1 (de) 2004-10-15

Family

ID=24387103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905709T ATE276275T1 (de) 1996-01-31 1997-01-30 Mhc-komplexe und ihre verwendungen

Country Status (9)

Country Link
US (3) US5869270A (de)
EP (2) EP1526141A3 (de)
JP (1) JP2000515363A (de)
AT (1) ATE276275T1 (de)
AU (1) AU729672B2 (de)
CA (1) CA2244755A1 (de)
DE (1) DE69730693T2 (de)
DK (1) DK0877760T3 (de)
WO (1) WO1997028191A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
CA2250166A1 (en) * 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6211342B1 (en) * 1996-07-18 2001-04-03 Children's Hospital Medical Center Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
ATE423789T1 (de) * 1997-09-16 2009-03-15 Univ Oregon Health & Science Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t- zellen
US6232445B1 (en) * 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
GB2339782A (en) * 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
EP1168918A4 (de) * 1999-03-03 2002-08-21 Univ Pennsylvania Impfstoff- und gentherapiezusammensetzungen und verfahren zu ihrer herstellung und verwendung
EP1179176B1 (de) * 1999-04-16 2006-04-05 Ortho-McNeil Pharmaceutical, Inc. Verfahren zur detektion von antigenspezifischen t-zellen
SG143935A1 (en) * 1999-05-06 2008-07-29 Univ Wake Forest Compositions and methods for identifying antigens which elicit an immune response
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US6995237B1 (en) * 1999-10-27 2006-02-07 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
US6316256B1 (en) * 2000-01-03 2001-11-13 Tr Associates, L.L.C. Method for protein transfer
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
IL151860A0 (en) * 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020006397A1 (en) * 2000-04-28 2002-01-17 Roberts Bruce L. In VIVO loading of MHC
CA2410642A1 (en) * 2000-05-25 2001-11-29 Sunol Molecular Corporation Modulation of t-cell receptor interactions
GB0110547D0 (en) * 2001-04-30 2001-06-20 Avidex Ltd Method
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
CA2487779C (en) 2001-06-05 2012-10-02 Altor Bioscience Corporation P53 binding t cell receptor molecules and uses thereof
US8022190B2 (en) 2001-06-19 2011-09-20 Technion Research & Development Foundation Ltd. Immuno-molecules containing viral proteins, compositions thereof and methods of using
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2003029475A1 (fr) * 2001-09-28 2003-04-10 Dnavec Research Inc. Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
EP1470161A1 (de) * 2002-01-18 2004-10-27 Inovio AS Bispezifische antikörper-dna-konstrukte für die intramuskuläre verabreichung
US20030199024A1 (en) * 2002-04-19 2003-10-23 Hansen Ted H. Single chain trimers of class I MHC molecules
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
AU2003253684A1 (en) * 2002-06-28 2004-01-19 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
CA2492200A1 (en) * 2002-07-12 2004-01-22 Dana-Farber Cancer Institute, Inc. Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
KR20050062572A (ko) * 2002-10-01 2005-06-23 가부시키가이샤 디나벡크 겐큐쇼 ＴＡＰ 활성의 저해에 의해 ＭＨＣ ｃｌａｓｓ Ⅰ에 의한외래 에피토프의 제시를 증강시키는 방법
CA2501946C (en) * 2002-10-16 2014-12-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP2316844A3 (de) * 2003-05-21 2011-07-20 Biotech Tools S.A. Peptidkomplex
US8436136B2 (en) 2003-05-21 2013-05-07 Biotech Tools S.A. Peptide complex
WO2005044982A2 (en) * 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2004289316B2 (en) 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
US20050227351A1 (en) * 2004-04-08 2005-10-13 Awdalla Essam T Methods and compound protein molecules used for inducing cytotoxic cell-mediated immune response in a mammal against a pathogenic cell
DE102004019803A1 (de) * 2004-04-23 2005-11-10 Imusyn Gmbh & Co.Kg Verfahren zur Herstellung löslicher MHC-Proteine
GB2422834B8 (en) * 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
EP1982176A1 (de) * 2006-01-30 2008-10-22 Dako Denmark A/S Quantifizierung antigenspezifischer t-zellen in vollblut mit hoher geschwindigkeit mittels durchflusszytometrie
US8518697B2 (en) * 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
ZA200810677B (en) * 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US20110124019A1 (en) * 2009-11-25 2011-05-26 The Charlotte-Mecklenburg Hospital Authority Method of using carbonic anhydrase to detect hemolysis
JP5665021B2 (ja) * 2010-03-08 2015-02-04 国立大学法人東京農工大学 融合ｍｈｃ分子連結磁気微粒子、抗原ペプチドのスクリーニング方法、組換えベクター、及び磁性細菌の形質転換体
WO2011147894A1 (en) 2010-05-25 2011-12-01 Forschungsverbund Berlin E.V. Chimeric mhc class ii proteinpeptide
GB201013767D0 (en) * 2010-08-17 2010-09-29 Isis Innovation Identification of ligands and their use
DK2699593T4 (da) 2011-04-20 2021-02-08 Univ Washington Through Its Center For Commercialization Beta-2 mikroglobulin-deficiente celler
US8753309B2 (en) 2011-06-24 2014-06-17 The Invention Science Fund I, Llc Device, system, and method including micro-patterned cell treatment array
US10228312B2 (en) 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
WO2013142965A1 (en) 2012-03-27 2013-10-03 The University Of Western Ontario Sh2 domain variants
EP2838548B1 (de) * 2012-04-17 2023-07-19 University of Washington through its Center for Commercialization Hla klasse ii defiziente zellen, hla i defiziente tellen fähig hla klasse ii proteine zu exprimieren und deren verwendung
EP2847322B1 (de) * 2012-05-08 2019-06-26 Western University Of Health Sciences Standardisierte ex-vivo-plattformen zur antigenspezifischen expansion der cd4+-t-zell-populationen
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
US9975944B2 (en) 2013-03-12 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
GB201313352D0 (en) 2013-07-26 2013-09-11 Isis Innovation Identification of peptide ligands
DK3480213T3 (da) * 2014-06-18 2020-02-17 Albert Einstein College Medicine Syntac-polypeptider og anvendelser deraf
EP3193592A1 (de) 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimäre antigenrezeptoren
WO2017068425A1 (en) 2015-10-22 2017-04-27 Juno Therapeutics Gmbh Methods for culturing cells and kits and apparatus for same
RU2021134624A (ru) 2015-10-22 2022-03-15 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
BR112018073606A2 (pt) 2016-05-18 2019-02-26 Cue Biopharma, Inc. polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos
EP3458095A4 (de) 2016-05-18 2019-11-27 Albert Einstein College of Medicine Variante pd-l1-polypeptide, t-zell-modulierende multimere polypeptide und verfahren zur verwendung davon
JP7219212B2 (ja) 2016-09-06 2023-02-07 エフ．ホフマン－ラ ロシュ アーゲー Ｍｈｃ結合ペプチドアレイおよびその使用方法
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN111010875B (zh) 2017-03-15 2024-04-05 库尔生物制药有限公司 用于调节免疫应答的方法
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
AU2020204994A1 (en) * 2019-01-03 2021-07-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
EP4149534A4 (de) 2020-05-12 2024-09-04 Cue Biopharma, Inc. Multimere t-zell-modulierende polypeptide und verfahren zur verwendung davon
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
EP4228693A4 (de) 2020-10-13 2024-12-18 Janssen Biotech, Inc. Biotechnologisch hergestellte t-zell-vermittelte immunität, materialien und andere verfahren zur modulation eines clusters der differenzierung iv und/oder viii

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE130197T1 (de) * 1988-06-14 1995-12-15 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
US5976551A (en) * 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
JPH07501526A (ja) * 1991-11-19 1995-02-16 アナージェン，インコーポレイティド 有害な免疫応答の改善において有用なｍｈｃサブユニット結合体
US5583031A (en) * 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
AU6270794A (en) * 1993-02-25 1994-09-14 Anergen, Inc. Treatment of allergic responses using mhc-peptide complexes
AU6715094A (en) * 1993-04-29 1994-11-21 Andrew Atkin Recombinant vaccine
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
DE69519101T3 (de) * 1994-07-29 2010-08-05 Sunol Molecular Corp., Miramar Mhc-komplexe und ihre verwendung
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
CA2224205A1 (en) * 1995-06-07 1996-12-19 Zymogenetics, Inc. Fused soluble mhc heterodimer-peptide complexes and their uses
US5869270A (en) 1996-01-31 1999-02-09 Sunol Molecular Corporation Single chain MHC complexes and uses thereof
CA2250166A1 (en) * 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof

Also Published As

Publication number Publication date
EP0877760A4 (de) 1998-12-30
WO1997028191A1 (en) 1997-08-07
US6309645B1 (en) 2001-10-30
US7141656B2 (en) 2006-11-28
EP1526141A3 (de) 2005-08-24
DE69730693T2 (de) 2005-10-06
US5869270A (en) 1999-02-09
AU2253897A (en) 1997-08-22
EP0877760B1 (de) 2004-09-15
CA2244755A1 (en) 1997-08-07
JP2000515363A (ja) 2000-11-21
EP1526141A2 (de) 2005-04-27
DE69730693D1 (de) 2004-10-21
DK0877760T3 (da) 2004-12-20
EP0877760A1 (de) 1998-11-18
AU729672B2 (en) 2001-02-08
US20020034513A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
ATE276275T1 (de) Mhc-komplexe und ihre verwendungen
CA2196085A1 (en) Mhc complexes and uses thereof
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE533784T1 (de) Lösliche, einzelkettige proteine des t- zellrezeptors
ES2090211T3 (es) Ensayos de fijacion a receptores, exentos de celulas, su produccion y utilizacion.
SE8904087D0 (sv) Peptide derivates
DK1012274T4 (da) Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
CY1110689T1 (el) Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
DE69841273D1 (de) Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
HU9201687D0 (en) Preparation of sets from peptid mixtures with polycomponents and their use for the identification of biologically active peptides
ATE213837T1 (de) Polypeptid-dendrimer komplexe
DE60119714D1 (de) Peptidderivat
ATE372382T1 (de) Ein faktor viii-polypeptid mit faktor viii:c- aktivität
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
NO962084L (no) DNA sekvens som koder for en BMP reseptor
ATE405582T1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
ES2150495T3 (es) Ligandos de flt3 purificados de mamifero y agonistas y antagonistas de los mismos.
EP2305710A3 (de) Synthetische Antikörperphagenbibliotheken
CA2301709A1 (en) Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
Harmand Molecular interface characterization in human bone matrix: I. Biochemical and IR spectroscopic studies
WO1996021028A3 (en) Soluble heterodimeric t cell receptors and their antibodies
EA200400384A1 (ru) Растворимый рецептор т-клетки
TH18474A (th) ลำดับดีเอนเอที่มีรหัสสำหรับหน่วยรับ bmp

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties